Hosking Partners LLP reduced its position in Bristol-Myers Squibb Co (NYSE:BMY) by 3.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,001 shares of the biopharmaceutical company’s stock after selling 7,565 shares during the period. Hosking Partners LLP’s holdings in Bristol-Myers Squibb were worth $10,604,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Capital Investment Counsel Inc raised its position in Bristol-Myers Squibb by 3.4% in the 4th quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 200 shares during the last quarter. Seizert Capital Partners LLC raised its position in Bristol-Myers Squibb by 3.8% in the 4th quarter. Seizert Capital Partners LLC now owns 6,069 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 224 shares during the last quarter. Banced Corp raised its position in Bristol-Myers Squibb by 2.3% in the 4th quarter. Banced Corp now owns 10,745 shares of the biopharmaceutical company’s stock valued at $559,000 after buying an additional 242 shares during the last quarter. Carroll Financial Associates Inc. increased its position in shares of Bristol-Myers Squibb by 1.5% during the 4th quarter. Carroll Financial Associates Inc. now owns 17,024 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 248 shares during the last quarter. Finally, Blume Capital Management Inc. increased its position in shares of Bristol-Myers Squibb by 11.9% during the 4th quarter. Blume Capital Management Inc. now owns 2,355 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 250 shares during the last quarter. Institutional investors own 73.35% of the company’s stock.

Several equities research analysts have recently issued reports on BMY shares. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, November 27th. BMO Capital Markets decreased their target price on Bristol-Myers Squibb to $56.00 and set a “market perform” rating for the company in a research report on Tuesday, November 27th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, December 7th. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, December 13th. Finally, Morgan Stanley set a $54.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $59.40.

Shares of BMY opened at $49.96 on Friday. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $67.44. The stock has a market capitalization of $80.88 billion, a P/E ratio of 12.55, a PEG ratio of 2.22 and a beta of 0.81. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The company had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter last year, the firm posted $0.68 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Sell-side analysts expect that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.

TRADEMARK VIOLATION NOTICE: “Hosking Partners LLP Sells 7,565 Shares of Bristol-Myers Squibb Co (BMY)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2019/03/17/hosking-partners-llp-sells-7565-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: What is the yield curve?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.